Abstract
Despite a 60-year history of discovery, trial and evaluation of scores of different compounds, there are no currently licensed effective antivirals for the common cold. The history of the development and abandonment of all potential compounds so far teaches us some important lessons for the continuation of our fight against colds. First, the common cold is a benign self-limiting condition, making the consumption of ‘harmless’ antivirals a requisite of prime importance for regulators. Second, the common cold is a syndrome caused by a myriad of known and unknown agents, which reduces the effectiveness of compounds that interfere with single specific agents or types of agents. The multifactorial nature of the genesis of colds makes it difficult for compounds showing in vitro efficacy to ‘make the jump’ to field effectiveness. Last, despite the heavy burden that the cold imposes on society, the vagueness and shortness of symptoms make it difficult for sufferers to present in time for physicians to prescribe antivirals, which are only effective if taken within a short time frame. Attention should be paid to the development of compounds with a non-virus-specific action.
Chapter PDF
Similar content being viewed by others
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Tyrrell DAJ (1988) Discovery of influenza viruses. In: Nicholson, Hay and Webster (eds). Textbook of Influenza. Blackwell, London, 19–26
Ferguson FR, Davey AFC, Topley WWC (1933) The value of mixed vaccines in the prevention of the common cold. JAMA 101:2042–49
Thompson KR (1991) Harvard Hospital and its volunteers. In: The story of the Common Cold Research Unit. Danny Howell Books, Warminster
Tyrrell DAJ (1990) The origins of the Common Cold Unit. J R Coll Physicians Lond 24:137–140
Tyrrell DAJ (1992) Acute respiratory virus infections. Indoor Environ 1:16–18
Clarke M, The 1944 patulin trial of the British Medical Research Council: An example of how concerted common purpose can get reliable answers to important questions very quickly. The James Lind Library (www.jameslindlibrary. org) (accessed 17 December 2008)
Chalmers I, Clarke M (2004) The 1944 patulin trial: The first properly controlled multicentre trial conducted under the aegis of the British Medical Research Council. Int J Epidemiol 32:253–260
Tyrrell DAJ (1992) A view from the common cold unit. Mini review. Antiviral Res 18:102–125
Merigan TC, Reed SE, Hall TS, Tyrrell DA (1973) Inhibition of respiratory virus infection by locally applied interferon. Lancet 1:563–7
Douglas RM, Moore BW, Miles HB et al. (1986) Prophylactic efficacy of intranasal alpha 2-interferon against rhinovirus infections in the family setting. N Engl J Med 314:65–70
Higgins PG, Barrow GI, Al-Nakib W et al. (1988) Failure to demonstrate synergy between alpha-interferon and a synthetic antiviral, enviroxime, in rhinovirus infections in volunteers. Antiviral Res 10:141–49
Gwaltney JM (1992) Combined antiviral and antimediator treatment of rhinovirus colds. J Infect Dis 166:776–82
Dolin R, Betts RF, Treanor J et al. (1983) Intranasally administered interferon as prophylaxis against experimentally induced influenza A infection in humans. In: Proceedings of 13th International congress of Chemotherapy, Vol. 60. Vienna, 20–23
Samo TC, Greenberg SB, Couch RB et al. (1983) Efficacy and tolerance of intranasally applied recombinant leukocyte A interferon in normal volunteers. J Infect Dis 148:535–42
Turner RB, Felton A, Kosak K et al. (1986) Prevention of experimental coronavirus colds with intranasal alpha-2b interferon. J Infect Dis 154:443–47
Panusarn C, Stanley ED, Dirda V (1974) Prevention of illness from rhinovirus infection by a topical interferon inducer. N Engl J Med 291:57–61
Gatmaitan BC, Stanley ED, Jackson GG (1973) The limited effect of nasal interferon induced by rhinovirus and a topical chemical inducer on the course of infection. J Infect Dis 127:401–7
Zerial A, Werner GH, Phillpotts RJ et (1985) Studies on 44 081 R.P., a new antirhinovirus compound, in cell cultures and in volunteers. Antimicrob Agents Chemother 27:846–50
Phillpotts RJ, Scott GM, Higgins PG et al. (1983) An effective dosage regimen for prophylaxis against rhinovirus infection by intranasal administration of HuINTERFERON-Alpha 2. Antiviral Res 3:121–36
Al-Nakib W, Higgins PG, Willman J et al. (1986) Prevention and treatment of experimental influenza A virus infection in volunteers with a new antiviral ICI 130,685. J Antimicrob Chemother 18:119–29
Higgins PG, Barrow GI, Tyrrell DAJ (1990) A study of the efficacy of the bradykinin antagonist NPC 567 in rhinovirus infection in human volunteers. Antiviral Res 14:339–44
Hayden FG, Tunkel AR, Treanor JJ et al. (1994) Oral LY217896 for prevention of experimental influenza A virus infection and illness in humans. Antimicrob Agents Chemother 38s:1178–81
Kahlich R, Klima J, Cihla F et al. (1979) Studies on efficacy of N-2-hydroxyethyl palmitamide (Impulsin) in acute respiratory infections. Serologically controlled field trials. J Hyg Epidemiol Microbiol Immunol 23:11–24
Hayden FG, Andries K, Janssen PAJ (1992) Safety and efficacy of intranasal Pirodavir (R 77975) in experimentally induced rhinovirus infection. Antimicrob Agents Chemother 36:727–32
Turner RB, Dutko FJ, Goldstein NH et al. (1993) Efficacy of oral WIN 54954 for prophylaxis of experimental rhinovirus infection. Antimicrob Agents Chemother 37:297–300
Togo Y, Schwartz AR, Hornick-RB (1973) Antiviral effect of 3, 4-dihydro-1-isoquinolineacetamide hydrochloride in experimental human rhinovirus infection. Antimicrob Agents Chemother 4:612–6
Soto AJ, Hall TS, Reed SE (1973) Trial of the antiviral action of isoprinosine against rhinovirus infection of volunteers. Antimicrob Agents Chemother 3:332–4
Waldman RH, Ganguly R (1977) Therapeutic efficacy of inosiplex (Isoprinosine) in rhinovirus infection. Ann NY Acad Sci 284:153–60
Phillpotts RJ, Higgins PG, Willman JS, et al. (1984) Intranasal lymphoblastoid interferon (‘wellferon’) prophylaxis against rhinovirus and influenza virus in volunteers. J Interferon Res 4:535–41
Al-Nakib W, Higgins PG, Barrow I, Tyrrell DA, Lenox-Smith I, Ishitsuka H (1987) Intranasal chalcone, Ro 09-0410, as prophylaxis against rhinovirus infection in human volunteers. J Antimicrob Chemother 20:887–92
Togo Y, Durr FE, Laurenzana DA (1977) Clinical evaluation of prophylactic intranasal 1-phenyl-3-(4-phenyl-2-thiazolyl) guanidine (CL 88,277) medication against rhinovirus 44 challenge. Med Microbiol Immunol (Berl) 163:37–44
Schiff GM, Sherwood JR (2000) Clinical activity of pleconaril in an experimentally induced coxsackievirus A21 respiratory infection. J Infect Dis 181:20–6
Hayden FG, Hassman HA, Coats T et al. (1999) Pleconaril treatment shortens duration of picornavirus respiratory illness in adults. 39th ICAAC September, Abstract LB-3
Switzer G (2003) How the media left the evidence out in the cold. BMJ 326:1403–4
Pevear DC, Hayden FG, Demenczuk TM, Barone LR, McKinlay MA, Collett MS (2005) Relationship of pleconaril susceptibility and clinical outcomes in treatment of common cold caused by rhinoviruses. Antimicrob Agents Chemother 49:4492–9
De Palma AM, Vliegen I, De Clercq E, Neyts J (2008) Selective inhibitors of picornavirus replication. Med Res Rev 28:823–84
Maugeri C, Alisi MA, Apicella C et al. (2008) New anti-viral drugs for the treatment of the common cold. Bioorg Med Chem 16:3091–107
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Additional information
This chapter is dedicated to the memory of Dr. David Tyrrell
Rights and permissions
Copyright information
© 2009 Birkhäuser Verlag Basel/Switzerland
About this chapter
Cite this chapter
Jefferson, T. (2009). Antivirals for the common cold. In: Eccles, R., Weber, O. (eds) Common Cold. Birkhäuser Advances in Infectious Diseases. Birkhäuser Basel. https://doi.org/10.1007/978-3-7643-9912-2_10
Download citation
DOI: https://doi.org/10.1007/978-3-7643-9912-2_10
Publisher Name: Birkhäuser Basel
Print ISBN: 978-3-7643-9894-1
Online ISBN: 978-3-7643-9912-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)